Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab’)2

Kim, Jin C.; Hong, Hyun K.; Lee, Kang H.; Ka, In H.; Roh, Seon Ae; Koo, Kum H.; Kim, Hee C.; Oh, Seung Won; Oh, Seong Jin; Kim, Jung S.; Park, Kun C.

doi:10.1007/s00432-005-0680-1

Cited by 2 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CEA and CA19-9) and metastasis-or angiogenesis-related factors such as MMP-7 and VEGF may be useful markers together with a cytological test. (37,(49)(50)(51)(52)(53) As the development of new drugs overcomes many intractable diseases, new regimens and drugs are needed to improve the poor prognosis of patients with peritoneal dissemination. We will introduce and propose agents that may be applicable for the treatment of peritoneal dissemination in the next section.…”

Section: Recent Advances In the Multimodal Therapy Of Peritoneal Dissmentioning

confidence: 99%

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

et al. 2006

View full text Add to dashboard Cite

Peritoneal dissemination is the most common cause of metastasis from malignancies in the abdominal cavity. There are no standard treatments for peritoneal dissemination and the results are poor. The reasons for this are as follows: (1) no effective chemotherapeutic agents have been identified or developed; (2) surgical cytoreduction has little effect on survival improvement; and (3) the molecular mechanisms of peritoneal dissemination have not been clarified and no therapy against the target molecules has been developed. However, studies on the molecular mechanisms of peritoneal dissemination have elucidated some of the target molecules and the development of new multimodal therapies has also improved survival. Early postoperative intraperitoneal chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and neoadjuvant intraperitoneal-systemic chemotherapy have been newly developed, and a novel surgical therapy named peritonectomy has been proposed to perform complete cytoreduction of peritoneal dissemination. At present, these approaches appear to be effective therapeutic modalities for peritoneal dissemination. However, TS-1 and capecitabine have shown worthwhile results in recent clinical trials for patients with advanced gastric cancer. We recently found that newly developed antitumor cytosine nucleoside analogs show a survival advantage in peritoneal dissemination models using human cancer cells. These non-fluoropyrimidine nucleosides may potentially help to improve the poor prognosis observed in patients with advanced cancers involving peritoneal dissemination. (Cancer Sci 2007; 98: 11-18) P eritoneal dissemination remains the most difficult type of metastasis to treat, and almost all surgeons believe that an operation is not indicated for such metastasis.(1-3) Systemic chemotherapy tends to have little effect on the treatment of peritoneal dissemination, because the peritoneal-blood barrier existing between mesothelial cells and the submesothelial capillary hinders drug distribution throughout the peritoneal cavity. Recent advances in the studies of new drugs and multimodal therapies have proposed the therapeutic potency for advanced cancer with peritoneal dissemination. Neoadjuvant chemotherapy is also known to reduce the tumor burden, thus resulting in a stage reduction. As a result, the incidence of complete cytoreduction may increase after neoadjuvant chemotherapy. A new type of neoadjuvant intraperitoneal-systemic chemotherapy (NIPS) has been developed to increase the rate of complete cytoreduction. The complete removal of peritoneal dissemination is an independent prognostic factor. A peritonectomy is a novel surgical procedure by which complete cytoreduction for peritoneal dissemination is performed.(5-8) These approaches are now being carried out as treatment modalities for peritoneal dissemination from appendiceal, colon and gastric cancer. Furthermore, several recent phase II studies that evaluated the efficacy of new anticancer drugs including taxanes, TS-1 and capecitabine have shown p...

show abstract

Section: Recent Advances In the Multimodal Therapy Of Peritoneal Dissmentioning

confidence: 99%

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

et al. 2006

View full text Add to dashboard Cite

show abstract

Radiation Dose to Surgical Staff From Positron-Emitter-Based Localization and Radiosurgery of Tumors

Heckathorne¹,

Dimock²,

Dahlbom³

2008

Health Physics

View full text Add to dashboard Cite

Surgical tissue characterization based on radiotracer uptake has become much more common in recent years, particularly due to the advent of the sentinel lymph node biopsy technique. Radiolabeled pharmaceuticals are used with hand-held gamma-sensitive probes, which are capable of localizing small tumors and lymph nodes that are first identified via scintigraphy. The radiation safety of such radioguided procedures, which typically employ 99mTc, has been well established. Now, with the emergence of 18F-fluorodeoxyglucose (18FDG) as a widely used tracer for PET imaging of cancer patients, there is increasing interest in the possibility of utilizing 18FDG for intraoperative tumor detection. First, though, the exposure to operating room personnel must be shown to be at a safe level. Due to the short half-life of 18F, the exposure rate will vary significantly with the start time post-injection as well as the duration of the procedure. The aim of this investigation is to determine empirically an exposure rate equation that can be integrated to estimate the exposure to a surgeon and assistants, from patients injected with 18FDG, over an arbitrarily chosen time interval. The study was conducted by measuring the radiation exposure rate from hospital in-patients receiving 18FDG-PET scans at various times from one to seven hours post injection; the empirical equation was determined from the plot of exposure rate vs. time for all patients. The resulting effective dose equivalent for the surgeon for typical values of injected activity, delay time and procedure duration was approximately 60 microSv.

show abstract

Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab’)2

Abstract: 125I-labeled T84.66 F(ab')2 efficiently targeted peritoneally disseminated gastric cancer cells, suggesting that RIGS using this immune agent may accurately detect occult peritoneal metastases in patients with gastric cancer.

Cited by 2 publications

References 29 publications

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

Radiation Dose to Surgical Staff From Positron-Emitter-Based Localization and Radiosurgery of Tumors

Contact Info

Product

Resources

About